+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients



Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients



Antimicrobial Agents and ChemoTherapy 62(11):



Hypermutable Pseudomonas aeruginosa organisms are prevalent in chronic respiratory infections and have been associated with reduced lung function in cystic fibrosis (CF); these isolates can become resistant to all antibiotics in monotherapy. This study aimed to evaluate the time course of bacterial killing and resistance of meropenem and ciprofloxacin in combination against hypermutable and nonhypermutable P. aeruginosa Static concentration time-kill experiments over 72 h assessed meropenem and ciprofloxacin in mono- and combination therapies against PAO1 (nonhypermutable), PAOΔmutS (hypermutable), and hypermutable isolates CW8, CW35, and CW44 obtained from CF patients with chronic respiratory infections. Meropenem (1 or 2 g every 8 h [q8h] as 3-h infusions and 3 g/day as a continuous infusion) and ciprofloxacin (400 mg q8h as 1-h infusions) in monotherapies and combinations were further evaluated in an 8-day hollow-fiber infection model study (HFIM) against CW44. Concentration-time profiles in lung epithelial lining fluid reflecting the pharmacokinetics in CF patients were simulated and counts of total and resistant bacteria determined. All data were analyzed by mechanism-based modeling (MBM). In the HFIM, all monotherapies resulted in rapid regrowth with resistance at 48 h. The maximum daily doses of 6 g meropenem (T>MIC of 80% to 88%) and 1.2 g ciprofloxacin (area under the concentration-time curve over 24 h in the steady state divided by the MIC [AUC/MIC], 176), both given intermittently, in monotherapy failed to suppress regrowth and resulted in substantial emergence of resistance (≥7.6 log10 CFU/ml resistant populations). The combination of these regimens achieved synergistic killing and suppressed resistance. MBM with subpopulation and mechanistic synergy yielded unbiased and precise curve fits. Thus, the combination of 6 g/day meropenem plus ciprofloxacin holds promise for future clinical evaluation against infections by susceptible hypermutable P. aeruginosa.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065310001

Download citation: RISBibTeXText

PMID: 30104278

DOI: 10.1128/aac.01150-18


Related references

Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study. Therapeutic Advances in Respiratory Disease 9(6): 272-280, 2015

Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections. Plos Genetics 10(10): E1004651, 2014

Hypermutable Pseudomonas aeruginosa in Cystic fibrosis patients from two Brazilian cities. Journal of Clinical Microbiology 51(3): 927-930, 2013

Detection and susceptiblility testing of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients. 2007

Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. Journal of Infectious Diseases 200(1): 118-130, 2009

Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrobial Agents and ChemoTherapy 49(6): 2276-2282, 2005

Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. Journal of Infectious Diseases 195(1): 70-80, 2007

Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Reviews of Infectious Diseases 7(Suppl. 4): S669-S674, 1985

Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Scandinavian Journal of Infectious Diseases. Supplementum 29: 64-69, 1981

Pseudomonas aeruginosa infection in cystic fibrosis bactericidal effect of serum from normal individuals and patients with cystic fibrosis on pseudomonas aeruginosa strains from patients with cystic fibrosis or other diseases. Acta Pathologica et Microbiologica Scandinavica Section C Immunology 85(2): 107-114, 1977

Comparative in vitro activity of meropenem against pseudomonas aeruginosa and pseudomonas maltophilia isolated from cystic fibrosis patients including imipenem resistant strains. Abstracts of the General Meeting of the American Society for Microbiology 91: 3, 1991

Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatrica Scandinavica 72(2): 283-287, 1983

Development of in vitro resistance to meropenem by Pseudomonas aeruginosa from cystic fibrosis patients. Abstracts of the General Meeting of the American Society for Microbiology 94: 14, 1994

Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma--possible synergism with Pseudomonas aeruginosa. Acta Paediatrica Scandinavica 70(5): 623-628, 1981

In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Journal of Antimicrobial ChemoTherapy 15(6): 679-684, 1985